Ahead Therapeutics


Ahead Therapeutics is a spin-off associated with the Immunology of Diabetes Research Group, led by Dr Marta Vives-Pi of the Germans Trias i Pujol Research Institute (IGTP) and the Supramolecular NanoChemistry and Materials Group, headed by ICREA Research Professor Daniel Maspoch at the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and including the researcher Dr Mary Cano.

The company was created in December 2017 to develop new therapies for auto-immune diseases. The therapy uses liposomes to halt the destructive reaction of the body's own tissues caused by diseases such as Type 1 diabetes or multiple sclerosis.


After carrying out published research over five years the scientists of the IGTP, ICN2 and ICREA have demonstrated the efficacy of an immunotherapy against auto-immunity.  The new strategy has been tried in animal models with type 1 diabetes and multiple sclerosis and opens the door to the prevention and treatment of auto-immune diseases.

The treatment consists of liposomes which simulate cells in the process of natural cell death to bring the mistaken reaction of the immune system against the body, typical of autoimmune disease, to a definitive halt.  Liposomes have been used in medicine before; they are small drops of liquid surrounded by a fatty exterior, very similar to the exterior of cells.  In the particular case of diabetes, when they are introduced into the body the liposomes are able to stop the destruction of insulin-producing pancreatic cells (beta cells) and prevent the disease from developing.


Responsable: Martí Dalmases

Address: Eureka Building · Parc de Recerca UAB (Campus UAB · 08193 Bellaterra)

E-mail: marti.dalmases@mac.com